Clinical Trial Update: Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating BMS-986497 (ORM-6151) as monotherapy and in dual/triple combinations with azacitidine and venetoclax in relapsed or refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• BMS-986497 (ORM-6151) (BMS-986497)
• Venetoclax (venetoclax)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: RECRUITING